Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
| Revenue (TTM) | $874.09M |
| Gross Profit (TTM) | $-60.60M |
| EBITDA | $-579.48M |
| Operating Margin | -38.20% |
| Return on Equity | -105.50% |
| Return on Assets | -12.40% |
| Revenue/Share (TTM) | $5.36 |
| Book Value | $2.65 |
| Price-to-Book | 15.17 |
| Price-to-Sales (TTM) | 7.38 |
| EV/Revenue | 7.13 |
| EV/EBITDA | 135.77 |
| Quarterly Earnings Growth (YoY) | -43.70% |
| Quarterly Revenue Growth (YoY) | -40.70% |
| Shares Outstanding | $166.18M |
| Float | $164.82M |
| % Insiders | 0.59% |
| % Institutions | 109.95% |
Volatility is currently expanding
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
The portfolio generated a negative absolute return but outpaced the Russell Midcap Growth Index. During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. We ended our investment campaign in Monolithic Power Systems, FTAI Aviation and Ionis Pharmaceuticals during the quarter.
Ionis Pharmaceuticals, Inc.'s independent launches should increasingly give it more exposure to its commercial successes going forward. For now, partner royalties also provide nice recurring revenues. And TRYNGOLZA's broader indication expands IONS revenue prospects as well. Similarly, DAWNZERA and ZANVASTRO help diversify IONS' pipeline. HIBSAGO also brings more royalty exposure to a different disease market.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from #2 last year to #1, Ionis was recognized for its industry-leading innovation, talented employees and strong values-based culture.“Being recognized as the #1 top employer by Science in only our second year of eligibility is a testament to the extr.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving NrtI therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication extension for TRYNGOLZA® (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]).
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN).
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IONS and any ticker you trade — then tracks every position and per-strategy win rate.
